This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Aug;31(5):403-7.

doi: 10.1016/j.ctrv.2005.05.003.

Docetaxel plus prednisone improves survival in men with advanced prostate cancer

Mike Shelley¹, Malcolm D Mason

Affiliations

PMID: 16169665
DOI: 10.1016/j.ctrv.2005.05.003

Comment

Docetaxel plus prednisone improves survival in men with advanced prostate cancer

Mike Shelley et al. Cancer Treat Rev. 2005 Aug.

. 2005 Aug;31(5):403-7.

doi: 10.1016/j.ctrv.2005.05.003.

Authors

Mike Shelley¹, Malcolm D Mason

Affiliation

¹ Cochrane Prostatic Diseases and Urological Cancers Group, Velindre NHS Trust, Cardiff, UK.

PMID: 16169665
DOI: 10.1016/j.ctrv.2005.05.003

No abstract available

PubMed Disclaimer

Comment on

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Tannock IF, et al. N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720. N Engl J Med. 2004. PMID: 15470213 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database